Sphingosine kinase 2 as the promising target for stroke research Dear Editor, Sphingosine kinase (SphK), lipid kinase, catalyzes the production of sphingosine-1-phosphate (S1P) from the precursor, sphingosine. Two forms of SphK are identified, SphK1 and SphK2, the latter being the more promising enzyme having the central role in cerebral ischemia or stroke. SphK2 is principally involved in the phosphorylation of the sphingosine analog fingolimod (FTY720), which is neuroprotective in rodent stroke models.
1 SphK2 is reported as a universal mediator that protects the isoflurane or hypoxia preconditioned mouse brain against ischemic injury. Previously, Wacker et al. 3 stated that the crucial role of SphK2 in hypoxic preconditioning induced ischemic tolerance in mice without a clear mechanism of action being involved. Later, they 4 found that Spkh2 regulates the junctional protein in blood-brain barrier and contributes to the hypoxic preconditioning-induced ischemic tolerance. Genetic deletion of SphK2 but not SphK1 increases the ischemic infarct size and worsens neurological function after transient middle cerebral artery occlusion in mice. Also, the protective effect of FTY720 is conserved in SphK1 knock-down mice but not in SphK2 knock-down mice, 1 suggesting the key involvement of SphK2 in neuroprotection following cerebral ischemic insult.
SphK2 promotes synthesis of S1P, which binds to the five-G-protein-coupled receptors (S1P 1-5 ), and undergoes several downstream signaling pathways, many of which are yet to be determined. Although there are compelling evidences suggesting the physiological role of SphK2 in mediating apoptosis, there are many studies supporting the role for SphK2 in promoting cell survival and proliferation. 5 The actual role of SphK2 in ischemic condition, whether it promotes penumbral neuron survivals or apoptosis, is still unknown. SphK1 has been widely investigated in different inflammatory conditions, and debated actions of SphK2 in inflammation have been purposed. 5 As inflammation is the most key factor for the neuronal damage following cerebral ischemia, the role of SphK2 in strokeinduced inflammation, immune cell infiltration, inflammatory cytokines production, etc. could be the key area for further stroke investigation. S1P plays the central role in immune cell functions by regulating lymphocyte egress from lymphoid tissues, and it appears that SphK2 may mediate this response by regulating the transport and circulation of S1P between tissues. The exact role of SphK2 in lymphocyte functioning during ischemic conditions needs to be confirmed. Encouragingly, SphK2 is reported to mediate the protective effects of ischemic preconditioning in cerebral and myocardial ischemic injury. Increased level of SphK2 mRNA in the brain is reported following cerebral ischemia. SphK2 activity and protein levels are rapidly and transiently upregulated in cerebral microvessels after hypoxic preconditioning. However, the downstream mechanism regarding the involvement of SphK2 in ischemic preconditioning has not been reported yet. Neubauer and Pitson's recent review 5 has enlightened the several issues regarding the role of SphK2 in different pathophysiological conditions; its function in cerebral ischemia needs further clarification. Taken together, there are few researches suggesting the promising role of SphK2 in cerebral ischemic conditions, and lots of questions still need to be answered through scientific investigation. If this could be done, SphK2 can act as the major bimolecular target for the future research in stroke.
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